Q-omics provides the consensus-scored REPS2 profile across patient tissues and cancer cell-line models. REPS2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, REPS2 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, REPS2 protein abundance shows 26,703 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where REPS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for REPS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes REPS2 survival associations across molecular data types. REPS2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible REPS2 RNA expression–survival associations across cancer types. High REPS2 expression shows unfavorable associations in PAAD and OV, but favorable associations in KIRC, LGG, HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for REPS2 RNA expression.
This table summarizes REPS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for REPS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. REPS2 shows lower tumor expression in KICH, LUSC, LUAD and THCA and higher tumor expression in BRCA and STAD. The KICH box plot shows higher REPS2 RNA expression in normal versus tumor tissue (log2 FC = −3.209, t-test p < 0.001).
This table shows molecular features associated with REPS2 in patient tissues and cancer cell lines. In patient samples, REPS2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, REPS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
